Bertolotto M, Freeman S, Richenberg J, Belfield J, Dogra V, Huang DY, Lotti F, Markiet K, Nikolic O, Ramanathan S, Ramchandani P, Rocher L, Secil M, Sidhu PS, Skrobisz K, Studniarek M, Tsili A, Turgut AT, Pavlica P, Derchi LE, Members of the ESUR-SPIWG WG
In 2014, Saxenda was the first GLP-1 introduced specifically for chronic weight management, followed by Wegovy in 2021 and Zepbound in 2023
With the successful data obtained from the initial phase, Viking Therapeutics is poised to move forward with a Phase 2 study of the oral VK2735 formulation in patients with obesity in the latter part of this calendar year
Det finnes ogs spesielle pakker som lover mange spinn fordelt over flere dager